How Important is Early Therapy in Axial Spondyloarthritis?

Rheumatic Disease Clinics of North America

Volumn 38, Issue 3, 2012, Pages 635-642

  Sieper, Joachim ^a   Braun, Jürgen ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b RHEUMAZENTRUM RUHRGEBIET   (Germany)

Author keywords

Axial spondyloarthritis; NSAIDs; TNF blockers

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; NAPROXEN; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; AXIAL SPONDYLOARTHRITIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; OSSIFICATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; REVIEW; SPONDYLARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; PROGNOSIS; REMISSION INDUCTION; SPINE; SPONDYLARTHRITIS; TIME-TO-TREATMENT; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867769772     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2012.08.001     Document Type: Review

References (37)

1. Braun J., van den Berg R., Baraliakos X., et al. 2010 Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011, 70(6):896-904.
2. Haibel H., Rudwaleit M., Listing J., et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005, 64(2):296-298.
3. Song I.H., Heldmann F., Rudwaleit M., et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011, 70(6):1108-1110.
4. Rudwaleit M., Listing J., Brandt J., et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004, 63(6):665-670.
5. Rudwaleit M., van der Heijde D., Landewe R., et al. The development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68(6):777-783.
6. Anderson J.J., Baron G., van der Heijde D., et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44(8):1876-1886.
7. van der Heijde D., Dijkmans B., Geusens P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52(2):582-591.
8. van der Heijde D., Kivitz A., Schiff M.H., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54(7):2136-2146.
9. Davis J.C., Van Der Heijde D., Braun J., et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003, 48(11):3230-3236.
10. Rudwaleit M., Claudepierre P., Wordsworth P., et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009, 36(4):801-808.
11. Haibel H., Rudwaleit M., Listing J., et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008, 58(7):1981-1991.
12. Sieper J., van der Heijde D., Dougados M., et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2012, [Epub ahead of print].
13. Barkham N., Keen H.I., Coates L.C., et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009, 60(4):946-954.
14. Song I.H., Hermann K., Haibel H., et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011, 70(4):590-596.
15. Song I.H., Hermann K.G., Haibel H., et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after one year of treatment with etanercept-results from the ESTHER trial. Ann Rheum Dis 2012, 71(Suppl 3):247.
16. Sieper J., Lenaerts J., Wollenhaupt J., et al. Double-blind, placebo-controlled, 28-week trial of efficacy and safety of infliximab plus naproxen vs naproxen alone in patients with early active spondyloarthritis treated with a submaximal dose of NSAIDs: preliminary results of INFAST part I. Ann Rheum Dis 2012, 71(Suppl 3):247.
17. van der Heijde D., Baraf H.S., Ramos-Remus C., et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005, 52(4):1205-1215.
18. Sieper J., Klopsch T., Richter M., et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 2008, 67(3):323-329.
19. Baraliakos X., Listing J., Brandt J., et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005, 7(3):R439-R444.
20. Haibel H., Heldmann F., Rudwaleit M., et al. Long-term efficacy of adalimumab for patients with active, non-radiographic, axial spondyloarthritis who relapsed following adalimumab withdrawal. Ann Rheum Dis 2010, 69:59.
21. Song I.H., Althoff C.E., Haibel H., et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 2012, 71(7):1212-1215.
22. Barkham N., Keen H.I., Coates L.C., et al. Clinical response and time to active disease following infliximab therapy in patients with HLA-B27 positive very early ankylosing spondylitis. Ann Rheum Dis 2009, 68(Suppl 3):72.
23. Sieper J., Lenaerts J., Wollenhaupt J., et al. Double-blind, placebo-controlled, 28-week trial of efficacy and safety of infliximab plus naproxen vs naproxen alone in patients with early active spondyloarthritis treated with a submaximal dose of NSAIDs: preliminary results of INFAST part II. Ann Rheum Dis 2012, 71(Suppl 3):247.
24. Creemers M.C., Franssen M.J., van't Hof M.A., et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005, 64(1):127-129.
25. Wanders A., Heijde D., Landewe R., et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005, 52(6):1756-1765.
26. Poddubnyy D., Rudwaleit M., Haibel H., et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012, [Epub ahead of print].
27. Kroon F., Landewe R., Dougados M., et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012, [Epub ahead of print].
28. Baraliakos X., Landewe R., Hermann K.G., et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 2005, 64(5):730-734.
29. Althoff C.E., Sieper J., Song I.H., et al. Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. Ann Rheum Dis 2012, [Epub ahead of print].
30. van der Heijde D., Landewe R., Baraliakos X., et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008, 58(10):3063-3070.
31. Song I.H., Hermann K.G., Haibel H., et al. Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis 2011, 70(7):1257-1263.
32. Vastesaeger N., van der Heijde D., Inman R.D., et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011, 70(6):973-981.
33. Rudwaleit M., Schwarzlose S., Hilgert E.S., et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008, 67(9):1276-1281.
34. Sieper J., van der Heijde D., Dougados M., et al. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 2012, 71(5):700-706.
35. Kiltz U., Baraliakos X., Karakostas P., et al. The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. Ann Rheum Dis 2012, 71(7):1207-1211.
36. van der Heijde D., Lie E., Kvien T.K., et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68(12):1811-1818.
37. van der Heijde D., Sieper J., Maksymowych W.P., et al. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011, 70(6):905-908.